查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1926882

Glucagon-Like Peptide-1促效剂市场（依产品、适应症、给药途径、通路及最终用户划分）－2026-2032年全球预测

Glucagon Like Peptide-1 Agonists Market by Product, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，Glucagon-Like Peptide-1促效剂市值将达到 134.1 亿美元，到 2026 年将成长至 145.8 亿美元，到 2032 年将达到 254.3 亿美元，复合年增长率为 9.56%。

关键市场统计数据
基准年 2025 134.1亿美元
预计年份：2026年 145.8亿美元
预测年份 2032 254.3亿美元
复合年增长率 (%) 9.56%

明确阐述GLP-1受体促效剂的临床发展方向、给药创新、支付方考量、对相关人员的策略意义

Glucagon-Like Peptide-1(GLP-1) 受体促效剂类药物已迅速从糖尿病的小众治疗领域发展成为内分泌、肥胖和基层医疗等多个临床和商业性领域的热门疗法。过去十年，胜肽工程、製剂和递送技术的进步不断突破疗效的界限，同时也刺激了新的处方行为和支付方的兴趣。因此，研究、生产、分销和临床护理等各个环节的相关人员正在重新评估关于患者治疗路径、治疗连续性和疗效评估的假设。

科学突破、监管调整、商业模式演变和供应链韧性如何共同重塑GLP-1治疗领域的格局

在科学、监管和商业性因素的驱动下，GLP-1治疗领域正经历变革性的转变，这正在改变竞争格局和病患的用药途径。长效製剂和口服胜肽技术的突破性进展减轻了给药负担，增强了处方医师的信心，并使其得以在传统专科诊疗范围之外广泛应用。同时，来自大规模临床计画的新安全性和有效性证据正在影响指南制定委员会和支付方的审查流程，促使人们制定更完善的报销途径和用药管理方法。

评估2025年美国关税变化对GLP-1供应链策略、供应商多元化和商业性韧性的营运影响

2025年美国新贸易关税的实施对GLP-1的研发和商业化路径产生了多方面的影响，在不改变其临床价值提案的前提下，影响了筹资策略、生产计画和成本结构。初期，由于关税调整改变了相对进口成本，促使企业重新考虑供应商多元化，各组织面临重新评估原料和成品采购合约的奖励压力。因此，一些製造商加快了在地化策略和替代采购方案的实施，以降低关税波动和跨境物流延误的风险。

透过深入的細項分析，将产品变体、临床适应症、给药途径、通路和最终用户环境与策略重点连结起来。

详细的细分市场分析表明，产品层面的差异化是竞争定位的核心。Dulaglutide、Exenatide、Liraglutide和Semaglutide等分子展现出不同的临床特征、给药间隔和製剂选择，这些都会影响处方模式。这些差异与特定适应症的考量因素相互交织。针对肥胖症和第2型糖尿病的干预措施有不同的支付方式、临床终点和依从性预期，这些因素会影响商业策略和实证医学证据的产生重点。因此，任何药物的生命週期规划都应整合其治疗领域以及与每种适应症相关的独特临床和经济价值提案。

区域采用模式和营运需求（美洲、欧洲、中东和非洲、亚太地区）指导区域打入市场策略和证据策略。

美洲、欧洲、中东和非洲以及亚太地区GLP-1疗法的区域趋势呈现出不同的应用驱动因素和营运考量，因此需要采取量身定制的商业化和临床应用策略。在美洲，法规结构、支付方结构以及与基层医疗的整合促进了GLP-1疗法在特定临床领域的快速应用，但处方行为仍受到报销模式和专科医疗服务可近性的影响。因此，该地区的策略往往侧重于支付方证据基础、真实世界结果的收集以及与综合医疗系统的合作，以证明GLP-1疗法在不同患者群体中的价值。

竞争格局洞察突显了科学差异化、策略伙伴关係和生产规模如何塑造领导企业的市场定位

GLP-1领域企业间的竞争反映了科学差异化、策略伙伴关係和规模经济的综合作用。领先的生物製药公司正投资于新一代製剂、拓展适应症和给药技术，而生物技术创新者则专注于口服胜肽类药物递送、新型辅料和器械整合等细分市场优势。与契约製造、专科药房和数位医疗服务提供者建立合作关係，正成为加速商业化和扩大患者支持的热门途径。

为确保竞争优势，应优先采取实际的行动，整合证据产生、供应链多元化、通路优化和伙伴关係策略。

为了因应不断发展的GLP-1市场，产业领导者应制定一项优先行动计划，重点关注临床差异化、供应链韧性、与支付方合作以及以患者为中心的服务模式。首先，企业应加快收集比较疗效和真实世界依从性数据，以证明GLP-1在肥胖症和第2型糖尿病适应症中的价值，并透过产生符合支付方和指南决策标准的证据来支持更广泛的市场准入。其次，透过多元化采购管道并加强与契约製造组织（CMO）的合作，可以确保关键临床项目的持续供应，同时降低关税和地缘政治风险。

为了支持研究结果和建议，采用了透明且可重复的调查方法，整合了临床文献、监管资讯来源、专家访谈和情境分析。

本分析整合了同行评审文献、监管指导文件、公开临床试验註册库以及对临床医生、供应链高管和支付方代表的专家访谈，从而构建了一套透明且可复製的调查方法。资料点来自多个资讯来源，并经过三角验证，应用于一个整合的工作流程，该流程能够区分原始临床证据、营运情报和商业性讯号。专家咨询旨在深入了解处方行为、报销决策的驱动因素以及物流限制，并将这些发现与已记录的政策变化和行业公告进行反覆检验。

一份简洁的临床、营运和政策见解综合报告，重点阐述了GLP-1疗法面临的策略挑战以及实现持续临床和商业性影响的途径。

总而言之，GLP-1疗法的市场环境呈现出临床创新、给药方式不断演进以及商业性模式转变交汇融合的特点，这些因素共同为相关人员创造了机会，同时也带来了挑战。製剂和给药途径的进步正在扩大潜在患者群体，但成功取决于临床证据、支付方合作以及营运执行的协调一致。不断变化的供应链和贸易政策凸显了製定积极主动的筹资策略策略的必要性，而区域差异则要求采取个人化的商业化和循证方法，以实现持续的药物可及性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章Glucagon-Like Peptide-1促效剂市场产品

  • Dulaglutide
  • Exenatide
  • Liraglutide
  • Semaglutide

第九章Glucagon-Like Peptide-1促效剂市场依适应症划分

  • 肥胖
  • 2型糖尿病

第十章Glucagon-Like Peptide-1促效剂市场依给药途径划分

  • 口服
  • 皮下注射

第十一章Glucagon-Like Peptide-1促效剂市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章Glucagon-Like Peptide-1促效剂市场（依最终用户划分）

  • 诊所
  • 居家医疗
  • 医院

第十三章 各地区Glucagon-Like Peptide-1促效剂市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章Glucagon-Like Peptide-1促效剂市场（按组别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国Glucagon-Like Peptide-1促效剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国Glucagon-Like Peptide-1促效剂市场

17. 中国Glucagon-Like Peptide-1促效剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen
  • AstraZeneca
  • Boehringer Ingelheim
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi
  • Sun Pharmaceutical Industries
  • Viking Therapeutics
  • Zealand Pharma
Product Code: MRR-4F7A6D4FF354

The Glucagon Like Peptide-1 Agonists Market was valued at USD 13.41 billion in 2025 and is projected to grow to USD 14.58 billion in 2026, with a CAGR of 9.56%, reaching USD 25.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.41 billion
Estimated Year [2026] USD 14.58 billion
Forecast Year [2032] USD 25.43 billion
CAGR (%) 9.56%

A clear orientation to GLP-1 receptor agonists capturing their clinical evolution, delivery innovations, payer considerations, and strategic implications for stakeholders

The therapeutic class of glucagon like peptide-1 receptor agonists has evolved rapidly from a niche diabetes intervention to a broad clinical and commercial focus that intersects endocrinology, obesity care, and primary care practice. Over the past decade, advances in peptide engineering, formulation, and delivery have raised the therapeutic ceiling while catalyzing new prescribing behaviors and payer interest. As a result, stakeholders across research, manufacturing, distribution, and clinical care are reassessing assumptions about patient pathways, treatment persistence, and outcomes measurement.

In parallel, regulatory bodies have updated labeling considerations and real-world evidence requirements, prompting more rigorous post-approval safety monitoring and comparative effectiveness analyses. Consequently, product developers and commercialization teams have redirected resources toward lifecycle management, indication expansion, and adherence-supporting services. Taken together, these developments make an integrated view of clinical data, supply chain resilience, and stakeholder economics essential for any organization seeking to compete effectively within the GLP-1 ecosystem.

This introduction establishes the foundation for subsequent sections, which examine structural shifts, policy impacts, segmentation insights, regional dynamics, competitor behavior, recommended actions, and the methodological approach used to synthesize the available evidence and expert perspectives.

How scientific breakthroughs, regulatory recalibration, evolving commercial models, and supply chain resilience are together reshaping the GLP-1 therapeutic landscape

The GLP-1 therapeutic landscape is experiencing transformative shifts driven by scientific, regulatory, and commercial vectors that are altering competitive dynamics and patient access. Breakthroughs in long-acting formulations and oral peptide technologies have reduced administration burdens and expanded prescriber confidence, thereby enabling broader adoption beyond traditional specialist settings. At the same time, emerging safety and efficacy evidence from larger clinical programs has influenced guideline committees and payer review processes, prompting more nuanced reimbursement pathways and utilization management approaches.

Concurrently, commercial models are migrating from pure product sales toward integrated service offerings that support initiation, persistence, and remote monitoring. This transition reflects an understanding that real-world effectiveness depends on adherence and coordinated care, which many manufacturers and payers now seek to address through digital therapeutics partnerships and care management programs. Moreover, manufacturing and supply chain strategies are being revisited to secure active pharmaceutical ingredient sourcing, scale biologics production, and de-risk logistics in response to geopolitical and trade uncertainties. In sum, these shifts are creating a competitive environment where therapeutic differentiation is increasingly determined by the combination of clinical profile, delivery format, support services, and supply chain robustness.

Assessing the operational consequences of the 2025 United States tariff changes on GLP-1 supply chain strategies, supplier diversification, and commercial resilience

The imposition of new United States trade tariffs in 2025 has introduced layered effects across GLP-1 development and commercialization pathways, influencing sourcing strategies, production planning, and cost structures without altering clinical value propositions. Initially, organizations experienced immediate pressure to reassess procurement contracts for raw materials and finished goods, as tariff schedules changed relative import costs and created incentives to reexamine supplier diversity. Consequently, several manufacturers accelerated localization strategies or contingency sourcing plans to mitigate exposure to tariff volatility and cross-border logistical delays.

As a result, contractual negotiations with contract manufacturers and ingredient suppliers have intensified, with greater emphasis on long-term agreements and collaborative risk-sharing mechanisms. In addition, organizations have increased investments in forecasting and scenario planning to model tariff-driven operational permutations and to preserve margin stability. Over time, these responses are likely to produce a more diversified manufacturing footprint and heightened emphasis on vertical integration where commercially feasible. Importantly, while tariffs influence cost dynamics and supply chain decisions, clinical development timelines and regulatory approval criteria remain the primary determinants of product adoption, and stakeholders are advised to balance cost mitigation with uninterrupted clinical supply and quality assurance.

Insightful segmentation analysis connecting product variants, clinical indications, administration routes, distribution pathways, and end-user settings to strategic priorities

A granular segmentation view reveals that product-level differentiation is central to competitive positioning, with molecules such as Dulaglutide, Exenatide, Liraglutide, and Semaglutide demonstrating varied clinical profiles, dosing intervals, and formulation opportunities that influence prescribing patterns. These distinctions intersect with indication-specific considerations: interventions targeting obesity versus type 2 diabetes attract different payer pathways, clinical endpoints, and adherence expectations, which in turn shape commercial strategies and evidence generation priorities. Thus, lifecycle planning for any given agent should integrate its therapeutic niche and the unique clinical and economic value propositions associated with each indication.

Route of administration further stratifies the landscape, as oral delivery options compete for convenience and primary care uptake while subcutaneous presentations retain advantages in predictable exposure and established clinician familiarity. Distribution strategies must align with these administration choices; hospital pharmacy channels play a pivotal role in initiating complex regimens and inpatient continuity, online pharmacy models support convenience and patient retention, and retail pharmacy networks facilitate broad community access and point-of-care counseling. End-user contexts add another layer of nuance, with clinics often responsible for initiation and titration protocols, homecare settings enabling adherence continuity and convenience-based delivery models, and hospitals providing acute management and multidisciplinary coordination. Integrating these segmentation lenses allows commercial and clinical leaders to prioritize resources, design differentiated service models, and tailor evidence generation to the specific decision-makers across the treatment pathway.

Regional adoption patterns and operational imperatives across the Americas, Europe Middle East and Africa, and Asia-Pacific that guide localized go-to-market and evidence strategies

Regional dynamics for GLP-1 therapies display distinct adoption drivers and operational considerations across the Americas, Europe Middle East and Africa, and Asia-Pacific, each requiring tailored approaches to commercialization and clinical engagement. In the Americas, regulatory frameworks, payer structures, and primary care integration have facilitated rapid uptake in certain clinical niches, yet prescribing remains sensitive to reimbursement models and specialty access. Therefore, strategies in this region often emphasize payer evidence dossiers, real-world outcomes collection, and collaboration with integrated health systems to demonstrate value in diverse patient populations.

Across Europe, the Middle East and Africa, heterogeneity in regulatory pathways and health technology assessment processes necessitates localized evidence strategies and flexible pricing mechanisms to navigate varied reimbursement environments. Stakeholders operating in these jurisdictions benefit from early HTA engagement and region-specific real-world evidence programs to address national decision criteria. In the Asia-Pacific region, rapid healthcare modernization, expanding primary care capacity, and increasing attention to metabolic disease management have created opportunities for scaled adoption, but success depends on culturally adapted patient support, supply chain scalability, and alignment with regional regulatory timelines. Recognizing these regional contrasts enables more precise go-to-market planning and allocation of resources where clinical impact and commercial traction are most attainable.

Competitive landscape insights highlighting how scientific differentiation, strategic partnerships, and manufacturing scale are shaping the leading players' positioning

Competitive dynamics among companies engaged in the GLP-1 space reflect a blend of scientific differentiation, strategic partnerships, and operational scale. Leading biopharma entities are investing in next-generation formulations, indication expansions, and delivery technologies, while biotech innovators focus on niche advantages such as oral peptide delivery, novel excipients, or device integration. Partnerships with contract manufacturers, specialty pharmacies, and digital health providers have become common levers to accelerate commercialization and extend patient support capabilities.

Consequently, organizational priorities vary by capability set: companies with extensive manufacturing capacity emphasize supply chain control and margin protection, those with strong clinical pipelines prioritize rapid evidence generation and regulatory sequencing, and commercially oriented players invest in channel orchestration and patient services. Across this spectrum, competitive differentiation increasingly depends on the ability to integrate clinical data with patient support systems, technology-enabled adherence solutions, and payer-aligned value propositions. Monitoring competitor moves in licensing, M&A, and distribution partnerships therefore remains essential for anticipating shifts in access and channel dynamics.

Practical prioritized actions for leaders to combine evidence generation, supply chain diversification, channel optimization, and partnership strategies to secure competitive advantage

Industry leaders should adopt a set of prioritized actions to navigate the evolving GLP-1 landscape, focusing on clinical differentiation, supply chain resilience, payer engagement, and patient-centric service models. First, companies must accelerate collection of comparative effectiveness and real-world adherence data that demonstrate value across both obesity and type 2 diabetes indications, aligning evidence generation with payer and guideline decision criteria to support broader access. Second, diversification of sourcing and increased collaboration with contract manufacturing organizations can mitigate tariff and geopolitical risk while preserving supply continuity for critical clinical programs.

Third, organizations should design channel strategies tailored to administration routes and end-user contexts, ensuring that oral delivery options are supported by primary care education and that subcutaneous therapies are paired with initiation and monitoring services. Fourth, investment in digital adherence tools and integrated care pathways will enhance persistence and outcomes, strengthening payer conversations and patient satisfaction. Finally, leaders should explore strategic partnerships and licensing arrangements that accelerate capability acquisition in areas such as oral peptide formulation, homecare delivery, and data analytics; such collaborations can compress time-to-value and spread development risk. Implementing these recommendations through cross-functional governance will enable faster, more coordinated responses to clinical, regulatory, and commercial challenges.

A transparent and reproducible research methodology integrating clinical literature, regulatory sources, expert interviews, and scenario analysis to underpin the study's findings and recommendations

This analysis synthesizes peer-reviewed literature, regulatory guidance documents, publicly available clinical trial registries, and expert interviews with clinicians, supply chain executives, and payer representatives to produce a transparent and reproducible methodology. Data points were triangulated across sources and subjected to a synthesis workflow that distinguishes primary clinical evidence from operational intelligence and commercial signals. Expert consultations were structured to capture perspectives on prescribing behavior, reimbursement decision drivers, and logistical constraints, and these insights were iteratively validated against documented policy changes and observed industry announcements.

Analytical frameworks included segmentation mapping, scenario analysis for tariff and supply chain responses, and comparative assessments of delivery formats and distribution channels. Quality assurance steps encompassed source cross-verification, consistency checks across datasets, and follow-up interviews to resolve discrepancies. Where applicable, real-world evidence interpretations prioritized outcomes that align with payer and clinician decision-making, such as adherence patterns and treatment persistence, rather than proprietary commercial metrics. Collectively, this methodological approach balances rigor with practical relevance to support actionable conclusions for stakeholders across the therapeutic, commercial, and regulatory spectrum.

A concise synthesis of clinical, operational, and policy insights that clarifies strategic imperatives and the pathways to sustained clinical and commercial impact in GLP-1 therapies

In synthesis, the GLP-1 therapeutic landscape is defined by converging clinical innovation, evolving delivery modalities, and shifting commercial paradigms that together present both opportunity and complexity for stakeholders. Advances in formulations and administration routes are broadening the potential patient base, yet success depends on the alignment of clinical evidence, payer engagement, and operational execution. Supply chain and trade policy developments underscore the need for proactive sourcing strategies, while regional heterogeneity requires tailored commercialization and evidence approaches to achieve durable access.

Therefore, organizations that invest in differentiated clinical data, robust supply chain planning, and patient-centric service models will be best positioned to translate therapeutic promise into sustained clinical impact and commercial viability. Cross-sector collaboration-spanning manufacturers, payers, care providers, and technology partners-will accelerate the formation of integrated care pathways that maximize the real-world benefits of GLP-1 therapies. Ultimately, strategic clarity, operational preparedness, and a relentless focus on patient outcomes will determine which stakeholders lead in this rapidly maturing therapeutic domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glucagon Like Peptide-1 Agonists Market, by Product

  • 8.1. Dulaglutide
  • 8.2. Exenatide
  • 8.3. Liraglutide
  • 8.4. Semaglutide

9. Glucagon Like Peptide-1 Agonists Market, by Indication

  • 9.1. Obesity
  • 9.2. Type 2 Diabetes

10. Glucagon Like Peptide-1 Agonists Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Subcutaneous

11. Glucagon Like Peptide-1 Agonists Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Glucagon Like Peptide-1 Agonists Market, by End User

  • 12.1. Clinic
  • 12.2. Homecare
  • 12.3. Hospital

13. Glucagon Like Peptide-1 Agonists Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Glucagon Like Peptide-1 Agonists Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Glucagon Like Peptide-1 Agonists Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Glucagon Like Peptide-1 Agonists Market

17. China Glucagon Like Peptide-1 Agonists Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen
  • 18.6. AstraZeneca
  • 18.7. Boehringer Ingelheim
  • 18.8. Dr. Reddy's Laboratories
  • 18.9. Eli Lilly and Company
  • 18.10. Novo Nordisk
  • 18.11. Pfizer
  • 18.12. Roche
  • 18.13. Sanofi
  • 18.14. Sun Pharmaceutical Industries
  • 18.15. Viking Therapeutics
  • 18.16. Zealand Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY EXENATIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY OBESITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GCC GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. G7 GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NATO GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA GLUCAGON LIKE PEPTIDE-1 AGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)